201 related articles for article (PubMed ID: 27170300)
41. PlenadrEMA: effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments: a study protocol for an open-label switch pilot study.
Boesen VB; Christoffersen T; Watt T; Borresen SW; Klose M; Feldt-Rasmussen U
BMJ Open; 2018 Jan; 8(1):e019487. PubMed ID: 29362269
[TBL] [Abstract][Full Text] [Related]
42. Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis.
Guarnotta V; Ciresi A; Pillitteri G; Giordano C
Clin Endocrinol (Oxf); 2018 May; 88(5):665-672. PubMed ID: 29368442
[TBL] [Abstract][Full Text] [Related]
43. The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism.
Wichers M; Springer W; Bidlingmaier F; Klingmüller D
Clin Endocrinol (Oxf); 1999 Jun; 50(6):759-65. PubMed ID: 10468948
[TBL] [Abstract][Full Text] [Related]
44. Systematic review and meta-analysis of the metabolic effects of modified-release hydrocortisone versus standard glucocorticoid replacement therapy in adults with adrenal insufficiency.
Bannon CA; Gallacher D; Hanson P; Randeva HS; Weickert MO; Barber TM
Clin Endocrinol (Oxf); 2020 Dec; 93(6):637-651. PubMed ID: 32621327
[TBL] [Abstract][Full Text] [Related]
45. Saliva and bloodspot cortisol: novel sampling methods to assess hydrocortisone replacement therapy in hypoadrenal patients.
Wong V; Yan T; Donald A; McLean M
Clin Endocrinol (Oxf); 2004 Jul; 61(1):131-7. PubMed ID: 15212655
[TBL] [Abstract][Full Text] [Related]
46. Current and future treatment options for adrenal insufficiency.
Arshad MF; Debono M
Curr Opin Endocrinol Diabetes Obes; 2021 Jun; 28(3):303-311. PubMed ID: 33782339
[TBL] [Abstract][Full Text] [Related]
47. Steroid use for refractory hypotension in congenital diaphragmatic hernia.
Robertson JO; Criss CN; Hsieh LB; Matsuko N; Gish JS; Mon RA; Johnson KN; Gadepalli SK
Pediatr Surg Int; 2017 Sep; 33(9):981-987. PubMed ID: 28685301
[TBL] [Abstract][Full Text] [Related]
48. Optimal glucocorticoid therapy.
Debono M; Ross RJ
Endocr Dev; 2011; 20():173-180. PubMed ID: 21164270
[TBL] [Abstract][Full Text] [Related]
49. Hydrocortisone replacement in disorders of sex development.
Blankenstein O
Endocr Dev; 2014; 27():160-71. PubMed ID: 25247653
[TBL] [Abstract][Full Text] [Related]
50. Health-related quality of life in primary and secondary adrenal insufficiency.
Aulinas A; Webb SM
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):873-88. PubMed ID: 25252879
[TBL] [Abstract][Full Text] [Related]
51. [Adrenal insufficiency and treatment with glucocorticosteroid].
Lindholm J
Ugeskr Laeger; 2016 Mar; 178(12):V10150788. PubMed ID: 27032433
[TBL] [Abstract][Full Text] [Related]
52. Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency.
Benson S; Neumann P; Unger N; Schedlowski M; Mann K; Elsenbruch S; Petersenn S
Eur J Endocrinol; 2012 Nov; 167(5):679-85. PubMed ID: 22930487
[TBL] [Abstract][Full Text] [Related]
53. Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients.
Behan LA; Rogers B; Hannon MJ; O'Kelly P; Tormey W; Smith D; Thompson CJ; Agha A
Clin Endocrinol (Oxf); 2011 Oct; 75(4):505-13. PubMed ID: 21521342
[TBL] [Abstract][Full Text] [Related]
54. Self-perceived health status of patients with adrenal insufficiency receiving glucocorticoid replacement therapy - French data from a worldwide patient survey.
Touraine P; Chenuc G; Colin C
Ann Endocrinol (Paris); 2015 Feb; 76(1):9-12. PubMed ID: 25573224
[TBL] [Abstract][Full Text] [Related]
55. Oral hydrocortisone administration in children with classic 21-hydroxylase deficiency leads to more synchronous joint GH and cortisol secretion.
Charmandari E; Pincus SM; Matthews DR; Johnston A; Brook CG; Hindmarsh PC
J Clin Endocrinol Metab; 2002 May; 87(5):2238-44. PubMed ID: 11994370
[TBL] [Abstract][Full Text] [Related]
56. Modified-release hydrocortisone to provide circadian cortisol profiles.
Debono M; Ghobadi C; Rostami-Hodjegan A; Huatan H; Campbell MJ; Newell-Price J; Darzy K; Merke DP; Arlt W; Ross RJ
J Clin Endocrinol Metab; 2009 May; 94(5):1548-54. PubMed ID: 19223520
[TBL] [Abstract][Full Text] [Related]
57. Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy.
Johannsson G; Falorni A; Skrtic S; Lennernäs H; Quinkler M; Monson JP; Stewart PM
Clin Endocrinol (Oxf); 2015 Jan; 82(1):2-11. PubMed ID: 25187037
[TBL] [Abstract][Full Text] [Related]
58. Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis.
Nowotny H; Ahmed SF; Bensing S; Beun JG; Brösamle M; Chifu I; Claahsen van der Grinten H; Clemente M; Falhammar H; Hahner S; Husebye E; Kristensen J; Loli P; Lajic S; Reisch N;
Endocrine; 2021 Mar; 71(3):586-594. PubMed ID: 33661460
[TBL] [Abstract][Full Text] [Related]
59. Why is the management of glucocorticoid deficiency still controversial: a review of the literature.
Crown A; Lightman S
Clin Endocrinol (Oxf); 2005 Nov; 63(5):483-92. PubMed ID: 16268798
[TBL] [Abstract][Full Text] [Related]
60. [Replacement therapy with adrenal steroids].
Hahner S; Allolio B
Internist (Berl); 2008 May; 49(5):545-6, 548-50, 552. PubMed ID: 18401570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
